Novartis Investor Presentation
New Novartis: Our strategy
Our focus
> Core Therapeutic Areas
Technology platforms
Priority geographies
Capital allocation / structure
Our priorities
Conclusion
Abbreviations
Full pipeline across Immunology covering Rheumatology,
Dermatology and Allergy
1. Core TAs - Immunology
Phase 1
Phase 2
Phase 3
Registration
6
Focus on areas of high unmet need in
Rheumatology, Dermatology and Allergy:
Sjögren's, Osteoarthritis, Food Allergy,
Hidradenitis Suppurativa, Lupus Nephritis,
Atopic Dermatitis
Developing novel and differentiated MoAs:
lanalumab: Fully human monoclonal antibody
binding to and blocking the function of the
BAFF receptor
Remibrutinib: Oral, covalent BTK inhibitor
targeting immune cell signaling
Disease area
Rheumatology
Dermatology
Allergy
Selected compound (indication)
Cosentyx® (300 mg Al)
CosentyxⓇ (IV PSA/IV axSpA/LN/GCA)
lanalumab (SjS/LN)
lanalumab (SLE)
LNA043 (Knee OA)
Remibrutinib (SjS)
MHV370 (SjS/SLE)
Cosentyx® (HS)
Remibrutinib (CSU)
CosentyxⓇ (LP)
Remibrutinib (HS)
MAS825 (HS)
XolairⓇ (FA)
Ligelizumab (FA)
Note: Bars in Gantt chart indicate current phase of development 1. Phase 2 initiating
Novartis Investor Presentation | September 22, 2022
Remibrutinib (FA)1
U
NOVARTIS | Reimagining MedicineView entire presentation